Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002.

Sennfält K, Carlsson P, Varenhorst E.

Eur Urol. 2006 Jun;49(6):1028-34. Epub 2006 Jan 6.

PMID:
16417962
2.

Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.

Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E.

Scand J Urol Nephrol. 2003;37(3):226-31.

PMID:
12775282
3.

Impact on health service costs of medical technologies used in management of prostatic cancer.

Holmberg H, Carlsson P, Kalman D, Varenhorst E.

Scand J Urol Nephrol. 1998 May;32(3):195-9.

PMID:
9689698
4.

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P.

Scand J Urol Nephrol. 2007;41(6):456-77.

PMID:
17934985
6.

Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

Zubek VB, Konski A.

Mol Diagn Ther. 2009;13(1):31-47. doi: 10.2165/01250444-200913010-00006.

PMID:
19351214
7.

International diffusion of new health technologies: a ten-country analysis of six health technologies.

Packer C, Simpson S, Stevens A; EuroScan: the European Information Network on New and Changing Health Technologies.

Int J Technol Assess Health Care. 2006 Fall;22(4):419-28.

PMID:
16984674
8.

Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.

Sadetsky N, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Prostate Cancer Prostatic Dis. 2008;11(3):280-7. Epub 2007 Sep 25.

PMID:
17893700
9.

Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Zeliadt SB, Penson DF.

Pharmacoeconomics. 2007;25(4):309-27. Review.

PMID:
17402804
10.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

11.

Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.

Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ.

Urology. 2007 Feb;69(2):311-4.

PMID:
17320670
12.

[Development of an Internet search strategy to identify new medical technologies in prostate cancer].

Thygesen M, Vondeling H, Douw K, Jønler M, Pedersen KV, Mommsen S.

Ugeskr Laeger. 2007 May 14;169(20):1912-6. Danish.

PMID:
17553371
13.

Trends in treatment costs for localized prostate cancer: the healthy screenee effect.

Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL.

Med Care. 2007 Feb;45(2):154-9.

PMID:
17224778
14.

Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer.

Jayadevappa R, Chhatre S, Wein AJ, Malkowicz SB.

Prostate. 2009 Jul 1;69(10):1067-76. doi: 10.1002/pros.20955.

PMID:
19343738
15.

Prostate cancer.

Penson DF, Chan JM; Urologic Diseases in America Project.

J Urol. 2007 Jun;177(6):2020-9.

PMID:
17509282
16.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
17.

Practitioner-level determinants of inappropriate prostate-specific antigen screening.

Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR.

Arch Intern Med. 2007 Jul 9;167(13):1367-72.

PMID:
17620529
18.

Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W.

Urology. 2006 Nov;68(5):1067-71. Epub 2006 Nov 7.

PMID:
17095070
19.

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH.

Eur Urol. 2006 Sep;50(3):475-82. Epub 2006 May 3.

PMID:
16713065
20.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

Supplemental Content

Support Center